Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

(2018) Denis Soulières et al.   CLINICAL CANCER RESEARCH

Does smoking alter the mutation profile of human papillomavirus–driven head and neck cancers?

(2018) Haitham Mirghani et al.   EUROPEAN JOURNAL OF CANCER

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

(2018) Renata Ferrarotto et al.   ORAL ONCOLOGY

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

(2018) Kevin J. Harrington et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.

(2018) Matthew H. Taylor et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

(2018) R Galot et al.   ANNALS OF ONCOLOGY

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Denis Soulières et al.   LANCET ONCOLOGY

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

(2017) Petr Szturz et al.   ORAL ONCOLOGY

Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma

(2017) Daniel L. Faden et al.   ORAL ONCOLOGY

New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors

(2017) Francesca De Felice et al.   ORAL ONCOLOGY

Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

(2017) Yi Cai et al.   Oncotarget

Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities

(2017) Shih-Chi Su et al.   Theranostics

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

(2016) Jessica L. Geiger et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes

(2016) Nezar Noor Al-hebshi et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular Profile of Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma Stratified by Smoking Status

(2016) J.P. Zevallos et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

(2016) Loren Michel et al.   ORAL ONCOLOGY

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

(2016) Jérôme Fayette et al.   Frontiers in Oncology

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) E. Massarelli et al.   ANNALS OF ONCOLOGY

Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer

(2015) Yassine Lalami et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer

(2015) Paul L. Swiecicki et al.   INVESTIGATIONAL NEW DRUGS

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) Jill Gilbert et al.   ORAL ONCOLOGY

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

(2015) Antonio Jimeno et al.   ORAL ONCOLOGY

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

(2015) N Mohell et al.   Cell Death & Disease

Response of Head and Neck Squamous Cell Carcinoma Cells CarryingPIK3CAMutations to Selected Targeted Therapies

(2015) Eric D. Wirtz et al.   JAMA Otolaryngology-Head & Neck Surgery

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

(2014) A. Jimeno et al.   ANNALS OF ONCOLOGY

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)†

(2014) V. Grünwald et al.   ANNALS OF ONCOLOGY

Tongue carcinoma infrequently harbor common actionable genetic alterations

(2014) Daniel SW Tan et al.   BMC CANCER

Therapeutic targeting of tumor suppressor genes

(2014) Luc G. T. Morris et al.   CANCER

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

(2014) Han Sang Kim et al.   CLINICAL CANCER RESEARCH

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

(2014) Tanguy Y. Seiwert et al.   CLINICAL CANCER RESEARCH

No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16INK4a status

(2014) Elena-Sophie Prigge et al.   HUMAN PATHOLOGY

APOBEC-Mediated Cytosine Deamination Links PIK3CA Helical Domain Mutations to Human Papillomavirus-Driven Tumor Development

(2014) Stephen Henderson et al.   Cell Reports

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

(2013) Athanassios Argiris et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition

(2013) X Chen et al.   ONCOGENE

A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)

(2013) Sewanti Limaye et al.   ORAL ONCOLOGY

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

(2013) Julie E. Bauman et al.   ORAL ONCOLOGY

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups

(2013)   Nature Communications

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

(2013) C. R. Pickering et al.   Cancer Discovery

Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors

(2013) Matthias Lechner et al.   Genome Medicine

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

(2012) A. R. Abdul Razak et al.   ANNALS OF ONCOLOGY

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

(2012) A. Argiris et al.   ANNALS OF ONCOLOGY

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

(2012) J. A. de Souza et al.   CLINICAL CANCER RESEARCH

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

(2011) Athanassios Argiris et al.   JOURNAL OF CLINICAL ONCOLOGY

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma

(2010) Jong-Lyel Roh et al.   ORAL ONCOLOGY

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck

(2008) W. H. Westra et al.   CLINICAL CANCER RESEARCH

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE